

REMARKS

Claims 1-13 are pending and are the subject of the office action. Claims 14-47 have been added in the amendment herein. Added claims 14-47 are fully supported by the application as filed and thus, do not introduce new matter.

In the office action, the Examiner indicated that copies of certain references previously cited by Applicants in their IDS were not present or considered (i.e., references cited as # 90, 103, 106, 115, 116, 122, 126, 167, 172, 179, 198, 204, 209, and 277 on the 1449 form). Enclosed with this paper are replacement copies of these references identified by the Examiner. It is requested that the Examiner indicate her consideration of these references with the next office communication.

Section 112 Rejections

Claims 1-5 and 10-13 were rejected under Section 112, first paragraph. Applicants respectfully disagree that the subject matter embodied by claims 1-5 and 10-13 is not enabled, as set forth by the Examiner. As the Examiner notes, the term "Apo-2 receptor" as employed in the claims is expressly defined in the specification, and those skilled in the art will readily appreciate those agonist antibodies which can be utilized in the claimed methods. Accordingly, it is believed that the claimed methods of claims 1-5 and 10-13 would not require undue experimentation. Withdrawal of these rejections is respectfully requested.

It is noted for clarity of the record that claims 14-47 have been added to further recite various embodiments of Applicants' invention, and are not intended as an acquiescence to the instant rejections.

Respectfully submitted,

GENENTECH, INC.

Date: September 17, 2003

By: 

Diane L. Marschang

Reg. No. 35,600

1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-5416